Surrozen, Inc. is a biotechnology firm dedicated to discovering and advancing pharmaceutical agents that precisely modify the Wnt pathway to facilitate tissue healing and regeneration. The company engineers specialized antibodies intended for use across a broad spectrum of medical conditions impacting organs such as the intestine, liver, eyes (retina, cornea), lungs, kidneys, inner ear (cochlea), skin, pancreas, and central nervous system. Key assets in their development pipeline include SZN-043, a tissue-targeted R-spondin mimetic designed to address severe liver ailments.